Chemiluminescence immunoassay (CLIA) is a high-sensitivity analytical technique that combines the specificity of antigen-antibody reactions with the precision of chemiluminescent detection, enabling the quantification of trace analytes at attomole concentrations. As one of the most advanced immunoassay platforms in modern laboratory medicine, CLIA is widely used for tumor marker screening, thyroid function testing, infectious disease diagnosis, and cardiac marker measurement. This article presents a comprehensive technical overview of CLIA principles, sample types, measurable analytes, detection methodologies, quality requirements, and practical applications.
Technical Overview
Chemiluminescence immunoassay (CLIA) is a label-based binding assay in which the intensity of light emitted by a chemical reaction is used to quantify an analyte captured through antigen-antibody recognition. Unlike fluorescence or absorbance methods, CLIA does not require an external excitation light source; instead, photons are generated spontaneously when a chemiluminescent label or substrate undergoes an oxidation reaction triggered by a chemical reagent. Because the background signal is extremely low and the emission is detected by a photomultiplier tube (PMT) operating in photon-counting mode, CLIA achieves detection limits in the range of 10⁻¹⁵ to 10⁻¹⁷ mol/L, which is one to three orders of magnitude better than conventional enzyme-linked immunosorbent assay (ELISA).
A typical CLIA system consists of four functional elements: a solid-phase or microparticle immobilization matrix (commonly paramagnetic particles coated with capture antibodies or antigens), a chemiluminescent label system, a separation mechanism that distinguishes bound from unbound fractions, and an optical detection unit integrated with automated fluidics. Modern fully automated analyzers perform sample aspiration, reagent dispensing, incubation, magnetic separation, washing, trigger-solution injection, and photon counting in a continuous workflow, delivering results in as little as 18 minutes per test with throughput exceeding 300 tests per hour on high-speed platforms.
Compared with radioimmunoassay (RIA), CLIA eliminates radioactive waste and offers superior reagent shelf life. Compared with ELISA, it provides higher sensitivity, a wider dynamic range spanning three to five orders of magnitude, better precision, and true random-access automation. These characteristics have made CLIA the dominant platform in clinical immunodiagnostics worldwide, and its design, manufacture, and use are governed by standards such as ISO 13485 for medical device quality management, ISO 15189 for medical laboratory competence, and relevant national standards of the GB series.
Testing Samples
Serum and Plasma
Serum collected in plain tubes and plasma collected in heparin or EDTA tubes are the most common sample matrices for CLIA. Serum is preferred for most tumor marker, hormone, and infectious disease assays, while lithium heparin plasma is acceptable on many platforms for rapid turnaround testing. Gross hemolysis, lipemia, and icterus should be avoided because they may interfere with optical detection and antigen-antibody binding. Samples are typically stable for 24 to 48 hours at 2–8 °C and for longer periods when frozen at −20 °C or below, depending on the analyte.
Whole Blood
Venous whole blood collected in EDTA anticoagulant is used for point-of-care and high-sensitivity cardiac assays, such as troponin and B-type natriuretic peptide, where rapid results directly influence clinical decisions. Some automated analyzers support closed-tube whole-blood sampling with automatic centrifugation or plasma separation modules to reduce pre-analytical errors and biohazard exposure.
Uine and Other Body Fluids
Random or first-morning urine specimens are used for assays such as human chorionic gonadotropin (hCG) and microalbumin. Cerebrospinal fluid, amniotic fluid, pleural or peritoneal effusions, and bronchoalveolar lavage fluid may also be analyzed for specific markers, provided the assay has been validated for that matrix. All specimens should be collected and transported following the manufacturer's instructions and the laboratory's documented pre-analytical procedures.
Testing Items
CLIA supports an extensive and continuously expanding test menu covering virtually all fields of immunoassay diagnostics:
- Tumor markers: alpha-fetoprotein (AFP), carcinoembryonic antigen (CEA), carbohydrate antigens CA 125, CA 15-3, CA 19-9, CA 72-4, total and free prostate-specific antigen (tPSA/fPSA), cytokeratin 19 fragments (CYFRA 21-1), neuron-specific enolase (NSE), squamous cell carcinoma antigen (SCC), pro-gastrin-releasing peptide (ProGRP), and human epididymis protein 4 (HE4).
- Thyroid function panel: thyroid-stimulating hormone (TSH), free and total triiodothyronine (FT3/TT3), free and total thyroxine (FT4/TT4), anti-thyroid peroxidase (anti-TPO), anti-thyroglobulin (anti-Tg), and TSH receptor antibodies (TRAb).
- Fertility and reproductive hormones: hCG, luteinizing hormone (LH), follicle-stimulating hormone (FSH), estradiol, progesterone, testosterone, prolactin, and anti-Müllerian hormone (AMH).
- Cardiac markers: high-sensitivity cardiac troponin I and T, creatine kinase-MB, myoglobin, B-type natriuretic peptide (BNP), N-terminal pro-BNP (NT-proBNP), D-dimer, and homocysteine.
- Infectious disease serology: hepatitis B panel (HBsAg, anti-HBs, HBeAg, anti-HBe, anti-HBc), hepatitis C antibody, hepatitis A antibody, HIV antigen-antibody combination, Treponema pallidum antibody, and rubella, TORCH, and Epstein-Barr virus panels.
- Metabolic and bone markers: 25-hydroxyvitamin D, ferritin, insulin, C-peptide, parathyroid hormone (PTH), cortisol, and growth hormone.
- Inflammation and autoimmunity: total and specific IgE, interleukin-6, anti-nuclear antibody profiles, and rheumatoid factor.
- Therapeutic drug monitoring: digoxin, tacrolimus, cyclosporine, and anti-epileptic drug concentrations.
Testing Methods
Direct Chemiluminescence with Acridinium Ester Labels
In direct CLIA, acridinium ester or acridinium sulfonamide derivatives are covalently conjugated to antibodies or antigens. In the presence of hydrogen peroxide and an alkaline trigger solution, the acridinium ring rapidly oxidizes and emits an intense flash of light within one to two seconds. Because the label is not enzyme-dependent and has low background, flash-type detection delivers excellent sensitivity and very short read times. The flash kinetics also minimize cross-talk between adjacent reaction cuvettes.
Chemiluminescent Enzyme Immunoassay (CLEIA)
CLEIA employs enzymes such as alkaline phosphatase (ALP) or horseradish peroxidase (HRP) as labels. Upon adding the corresponding chemiluminescent substrate, such as a stabilized dioxetane phosphate for ALP or luminol with enhancers for HRP, the enzymatic reaction produces a prolonged glow-type light emission. The enzymatic amplification effect provides very high sensitivity, and the glow kinetics simplify signal integration, making CLEIA one of the most widely implemented CLIA formats.
Electrochemiluminescence Immunoassay (ECLIA)
Electrochemiluminescence uses a ruthenium tris-bipyridine label that is oxidized at an electrode surface in the presence of tripropylamine, generating light in a reaction that is precisely controlled by the applied voltage. ECLIA offers outstanding sensitivity, an exceptionally wide dynamic range, and superior reagent stability, and it is commonly used for high-volume clinical panels.
Assay Formats and Workflow
Regardless of the label system, CLIA applies three principal immunoassay formats:
- Sandwich (two-site) format: the analyte is captured between a solid-phase antibody and a labeled second antibody; signal is directly proportional to analyte concentration. This format is used for large analytes with multiple epitopes, such as hormones with high molecular weight and tumor markers.
- Competitive format: the analyte in the sample competes with a labeled analog for a limited number of binding sites; signal is inversely proportional to analyte concentration. This format is used for small molecules such as steroids, thyroid hormones, and therapeutic drugs.
- Indirect and capture formats: used mainly for antibody detection, where antigen immobilized on the solid phase captures sample antibodies, which are then revealed by a labeled anti-human immunoglobulin, or where anti-human IgM captures specific IgM antibodies for the diagnosis of acute infections.
The general workflow comprises sample and reagent dispensing, incubation to reach binding equilibrium, magnetic or wash-based separation of the bound fraction, addition of the trigger or substrate reagent, photon counting by the PMT, and result calculation against a calibration curve, frequently using a lot-specific master curve with two-point recalibration. Analytical performance must be verified according to CLSI evaluation protocols and the laboratory's quality system, including precision, trueness, analytical sensitivity, linearity, and reference interval confirmation.
Applications
Chemiluminescence immunoassay is applied across a broad spectrum of laboratory and industrial fields:
- Clinical diagnostics: routine quantification of hormones, tumor markers, cardiac markers, vitamins, therapeutic drugs, and infectious disease antibodies in hospital core laboratories and reference laboratories.
- Oncology support: tumor marker monitoring for treatment response assessment, recurrence surveillance, and high-risk population screening in combination with imaging and pathology.
- Blood bank screening: serological screening of donated blood for hepatitis B and C, HIV, and syphilis markers under national blood safety regulations.
- Pharmaceutical and biopharmaceutical development: pharmacokinetic and pharmacodynamic assays, immunogenicity testing for anti-drug antibodies, and cytokine release studies in clinical trials.
- Food safety and veterinary diagnostics: detection of veterinary drug residues, allergens, and animal disease antibodies using CLIA-based screening kits validated by accredited third-party laboratories.
- Environmental and research applications: trace analysis of pollutants, endocrine disruptors, and biomolecules in academic and applied research settings.
Quality Assurance and Standards
Reliable CLIA performance depends on a comprehensive quality framework. Manufacturers must comply with ISO 13485 quality management requirements for in vitro diagnostic devices, while clinical laboratories operate under ISO 15189 accreditation. Daily practice includes internal quality control using at least two concentration levels per analyte, participation in external quality assessment programs, documented calibration verification, and traceability of measurement results to reference materials or reference measurement procedures where available. Reagents and analyzers should be used within their specified operating conditions, and method comparison or bridging studies should be performed when switching platforms, because tumor marker and hormone results may differ between assay systems.
FAQ
Q1: What makes CLIA more sensitive than ELISA?
CLIA detects photons emitted by a chemical reaction rather than absorbance of a colored product. The absence of an excitation source eliminates background scattering and autofluorescence, and photon-counting PMT detection amplifies even single molecular events, achieving detection limits of 10⁻¹⁵ to 10⁻¹⁷ mol/L.
Q2: What is the difference between CLIA, CLEIA, and ECLIA?
CLIA is the general term for any immunoassay using chemiluminescent detection. CLEIA is a subset in which an enzyme label converts a chemiluminescent substrate, and ECLIA is a subset in which light is generated electrochemically at an electrode surface using a ruthenium label.
Q3: How long does a CLIA test take?
On fully automated analyzers, the first result is typically reported in 18 to 60 minutes depending on the assay and platform, with subsequent results at intervals of a few minutes or less due to continuous random-access processing.
Q4: Which sample types are acceptable?
Serum and heparinized or EDTA plasma are most common; whole blood is supported for certain cardiac assays, and urine, cerebrospinal fluid, and other body fluids may be used for specific validated analytes. Interferents such as hemolysis, lipemia, biotin, and heterophilic antibodies should be assessed before reporting.
Q5: Can CLIA results be compared directly between different analyzers?
Not always. Because antibody specificity, calibration, and assay architecture differ among systems, patient monitoring should ideally be performed on a single platform. When a platform change is unavoidable, laboratories should conduct method comparison studies in accordance with CLSI guidance and document any reference interval adjustments.
Q6: Is CLIA suitable for high-volume laboratory automation?
Yes. Modern CLIA analyzers support bar-code sample identification, bidirectional connectivity to laboratory information systems, automatic re-runs, and track-based automation with throughputs of several hundred tests per hour, making CLIA the preferred platform for consolidated immunodiagnostics.